• Explore /
  • Poster
  • / Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): A single-arm, phase 2 trial.

Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): A single-arm, phase 2 trial.

Abstract Poster

Authors

null

Jared Cohen

Washington University Siteman Cancer Center, St. Louis, MO

Jared Cohen , Jessica C. Ley , Jingxia Liu , Emma Haselhorst , Peter John Oppelt , Douglas Adkins

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04643379

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 6016)

DOI

10.1200/JCO.2023.41.16_suppl.6016

Abstract #

6016

Poster Bd #

8

Abstract Disclosures

Similar Posters

First Author: E. Gabriela Chiorean

First Author: Vincent Chung

First Author: YunJung Kim

First Author: Elias Chandran